About Motif Bio PLC (LON:MTFB)
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:MTFB
- CUSIP: N/A
- Web: https://www.motifbio.com/
Capitalization:- Market Cap: £108.44 million
- Outstanding Shares: 262,878,000
Average Prices:- 50 Day Moving Avg: GBX 34.57
- 200 Day Moving Avg: GBX 31.80
- 52 Week Range: GBX 21.44 - GBX 53.50
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.02 per share
- Price / Book: 20.63
Profitability:- Return on Equity: -773.10%
- Return on Assets: -183.64%
Misc:- Average Volume: 1.67 million shs.
Frequently Asked Questions for Motif Bio PLC (LON:MTFB)
What is Motif Bio PLC's stock symbol?
Motif Bio PLC trades on the London Stock Exchange (LON) under the ticker symbol "MTFB."
Where is Motif Bio PLC's stock going? Where will Motif Bio PLC's stock price be in 2017?
5 brokers have issued 12 month price objectives for Motif Bio PLC's shares. Their predictions range from GBX 90 to GBX 110. On average, they expect Motif Bio PLC's share price to reach GBX 101.50 in the next year. View Analyst Ratings for Motif Bio PLC.
Who are some of Motif Bio PLC's key competitors?
Some companies that are related to Motif Bio PLC include Spring Bank Pharmaceuticals (SBPH), Mast Therapeutics (SVRA), OncoCyte Corp (OCX), Clearside Biomedical (CLSD), Aileron Therapeutics (ALRN), TOCAGEN INC (TOCA), OVID THERAPEUTC (OVID), Fate Therapeutics (FATE), Recro Pharma (REPH), Agile Therapeutics (AGRX), Vascular Biogenics (VBLT), Summit Therapeutics PLC (SMMT), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), Conatus Pharmaceuticals (CNAT), Dimension Therapeutics (DMTX), Adverum Biotechnologies (ADVM) and Cempra (CEMP).
Who are Motif Bio PLC's key executives?
Motif Bio PLC's management team includes the folowing people:
- Graham George Lumsden, Chief Executive Officer, Executive Director
- Robert Dickey IV, Chief Financial Officer
- Rajesh B. Shukla, Vice President - Clinical Operations
- Robert J. Bertoldi, Executive Director
- David Huang M.D. Ph.D., Chief Medical Officer
- Stephen Austin, Company Secretary
- Richard Cecil Eversfield Morgan, Non-Executive Chairman of the Board
- Craig T. Albanese, Non-Executive Director
- Charlotta Ginman-Jones, Non-Executive Director
- Jonathan E Gold, Non-Executive Director
How do I buy Motif Bio PLC stock?
Shares of Motif Bio PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Motif Bio PLC's stock price today?
One share of Motif Bio PLC stock can currently be purchased for approximately GBX 41.25.
MarketBeat Community Rating for Motif Bio PLC (LON MTFB)MarketBeat's community ratings are surveys of what our community members think about Motif Bio PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Motif Bio PLC (LON:MTFB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | GBX 101.50 |
Consensus Price Target History for Motif Bio PLC (LON:MTFB)
Analysts' Ratings History for Motif Bio PLC (LON:MTFB)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 10/5/2017 | Peel Hunt | Initiated Coverage | Buy | GBX 106 |  |
| 10/5/2017 | Northland Securities | Reiterated Rating | Buy | | |
| 10/4/2017 | FinnCap | Reiterated Rating | Buy | GBX 100 | |
| 10/2/2017 | Beaufort Securities | Reiterated Rating | Speculative Buy | GBX 110 | |
| 1/9/2017 | Rodman & Renshaw | Initiated Coverage | Buy | | |
| 11/11/2015 | Northland Capital Partners | Reiterated Rating | Buy | GBX 114 | |
(Data available from 10/22/2015 forward)
Earnings History for Motif Bio PLC (LON:MTFB)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Motif Bio PLC (LON:MTFB)Current Year EPS Consensus Estimate: $-25.11 EPS
Dividend History for Motif Bio PLC (LON:MTFB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Motif Bio PLC (LON:MTFB)Insider Trades by Quarter for Motif Bio PLC (LON:MTFB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/5/2015 | Stakes III,John Wilbur | Insider | Buy | 100,000 | GBX 60 | £60,000 | |
(Data available from 1/1/2013 forward)
Headline Trends for Motif Bio PLC (LON:MTFB)
Latest Headlines for Motif Bio PLC (LON:MTFB)
| Source: |
|
Loading headlines, please wait.
Motif Bio PLC (MTFB) Chart for Sunday, October, 22, 2017
